Oncogenic KRAS confers chemoresistance by upregulating NRF2.
about
The Nrf2/HO-1 Axis in Cancer Cell Growth and ChemoresistanceMolecular mechanisms of Nrf2 regulation and how these influence chemical modulation for disease interventionNrf2 and Notch Signaling in Lung Cancer: Near the CrossroadEmerging roles of Nrf2 signal in non-small cell lung cancerp62 links autophagy and Nrf2 signalingMechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative diseaseBrusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2.MicroRNA-134 targets KRAS to suppress breast cancer cell proliferation, migration and invasionPERK induces resistance to cell death elicited by endoplasmic reticulum stress and chemotherapy.Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2The toxic effects and possible mechanisms of Brusatol on mouse oocytesTamoxifen activates Nrf2-dependent SQSTM1 transcription to promote endometrial hyperplasiaCancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405.Activated Nrf2 Interacts with Kaposi's Sarcoma-Associated Herpesvirus Latency Protein LANA-1 and Host Protein KAP1 To Mediate Global Lytic Gene Repression.A Curcumin Derivative That Inhibits Vinyl Carbamate-Induced Lung Carcinogenesis via Activation of the Nrf2 Protective Response.Risk prediction model for epithelial ovarian cancer using molecular markers and clinical characteristics.Ginseng alleviates cyclophosphamide-induced hepatotoxicity via reversing disordered homeostasis of glutathione and bile acid.A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer.TGF-β and Hypoxia/Reoxygenation Promote Radioresistance of A549 Lung Cancer Cells through Activation of Nrf2 and EGFR.Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2KIAA1522 is a novel prognostic biomarker in patients with non-small cell lung cancer.Role of Nrf2 and Autophagy in Acute Lung InjuryMutations and expression of the NFE2L2/KEAP1/CUL3 pathway in Chinese patients with lung squamous cell carcinoma.Brusatol inhibits HIF-1 signaling pathway and suppresses glucose uptake under hypoxic conditions in HCT116 cells.Integrated molecular analysis reveals complex interactions between genomic and epigenomic alterations in esophageal adenocarcinomas.Inhibition of cancer antioxidant defense by natural compounds.The Dual Role of Nrf2 in Nonalcoholic Fatty Liver Disease: Regulation of Antioxidant Defenses and Hepatic Lipid Metabolism.Opportunities and challenges of radiotherapy for treating cancer.The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?Nrf2: a potential therapeutic target for naturally occurring anticancer drugs?Brusatol overcomes chemoresistance through inhibition of protein translation.Notch signaling in regulating angiogenesis in a 3D biomimetic environment.Application of Mass Spectrometry Profiling to Establish Brusatol as an Inhibitor of Global Protein Synthesis.Overexpression of microRNA-30a-5p inhibits liver cancer cell proliferation and induces apoptosis by targeting MTDH/PTEN/AKT pathway.MiRNAs-mediated cisplatin resistance in breast cancer.Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial.Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway.Perspectives of the Nrf-2 signaling pathway in cancer progression and therapy.Upregulation of CISD2 augments ROS homeostasis and contributes to tumorigenesis and poor prognosis of lung adenocarcinoma.KRAS overexpression independent of RAS mutations confers an adverse prognosis in cytogenetically normal acute myeloid leukemia.
P2860
Q26772298-C4F281B4-2C37-476E-8CED-67D0DF84118DQ26778356-3CAE7EA2-B74B-4CA1-AD7E-2F36A2299EA1Q28066915-AD08FF1D-0BD8-4907-8008-915525BE68BBQ28078928-BF6E2BBF-925F-4F35-A3E2-50C4EBF9444DQ28392820-58DD13C1-6C24-48E3-9A27-448D5F948074Q28394732-1BD2966A-1FF3-4636-B7B7-D683DA875F0BQ30614574-C2C04275-E3B4-43E8-A82F-DA7F1B609059Q33599411-DB094741-76AB-4394-B51B-6505B6683B7CQ33667531-A7522E3A-B5BC-4845-8E05-9BC8A5DBD1FFQ33688129-123841B6-A9C3-4C21-871D-302238D18ECAQ33704194-E034861A-2CF6-4094-B018-26CA043217E8Q33820998-DA9FB853-B0F6-4738-AF5A-31989443EB7BQ35753567-38B2B26A-4946-45E7-9C8B-BBA3F8415751Q35861265-32F48A0D-A276-4307-A61E-41E7C1D15DEDQ36030282-BF9EECAB-6959-40DB-A3F7-137C3D44BB05Q36199823-F142D111-7441-4B79-A648-F236AA3E7837Q36340043-F9CBE884-D7CF-408F-B4BB-F679EB2D3150Q36371799-CAD3486C-DA3F-4C9E-97BC-37A8B1506E80Q36556188-7A16F542-09B4-4962-93C4-4A76944D5CFEQ36561564-113E9CAB-4994-4E1C-A592-E218D911FBAFQ36819651-603E83A1-1B1B-4152-B8FC-E55A995E54F0Q36998874-D9C6327C-FC07-46B6-9CFB-89885B1D3081Q37121524-25103BB9-1761-499B-914C-264F60ADDA26Q37508566-AC16DC31-1A88-43EA-A7AE-8DA0D42FAD1DQ37593285-BF3A05C2-EA58-4B35-8276-97FEF18D821DQ37716657-602D05DC-61CA-48AD-AC94-CE8A8FDFB26EQ38539752-BAB47A18-B592-4B66-86CC-B623B5A53499Q38539957-566482B0-6632-4D5E-9476-FAF36A348B1EQ38612793-955001F2-206B-4BB2-B71B-675585A05766Q38694717-5540E1BC-AEFB-4678-95DF-A1C6962EE81DQ38724316-DE7FFE48-A653-4618-9476-0528473B27EAQ38805816-263CB21B-C446-4FF8-86AB-C8B6E135C07CQ38808418-955F7C38-950A-4BCD-BA90-CE21DF6D527BQ38818025-B871D98C-8F11-4028-88CA-43B9EA90DD8BQ38905681-2A424FA5-2294-4C4E-A1DC-B2E6BF7A6E18Q41069109-F53FECA7-798D-47BB-A1EF-DFB11A6434B9Q41627000-098F5A00-46F4-4D28-8BD2-CFFC015C22B5Q41678966-BE301A9C-A950-4D80-ADBA-16C699146956Q41717532-F474F8EF-2CD7-4AE6-A3C6-623775F29F34Q42371609-75B1B81C-FCF6-4C43-8E7B-0C74A6FA7FCE
P2860
Oncogenic KRAS confers chemoresistance by upregulating NRF2.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Oncogenic KRAS confers chemoresistance by upregulating NRF2.
@en
type
label
Oncogenic KRAS confers chemoresistance by upregulating NRF2.
@en
prefLabel
Oncogenic KRAS confers chemoresistance by upregulating NRF2.
@en
P2093
P2860
P1433
P1476
Oncogenic KRAS confers chemoresistance by upregulating NRF2.
@en
P2093
Aikseng Ooi
Donna D Zhang
Eli Chapman
Pak K Wong
Seyed Javad Moghaddam
Shasha Tao
P2860
P304
P356
10.1158/0008-5472.CAN-14-1439
P407
P577
2014-10-22T00:00:00Z